Skip to content

Comprehensive digital intervention study of smart wrist sphygmomanometer in prehypertensive patients combined with overweight

Comprehensive digital intervention study of smart wrist sphygmomanometer in prehypertensive patients combined with overweight

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200061133
Enrollment
Unknown
Registered
2022-06-15
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

experimental group:lose weight

Sponsors

Chinese PLA General Hospital, Beijing, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18-65; 2. No gender limitation; 3. Use a smart blood pressure watch to measure average household blood pressure: 120mmHg <= systolic < 135mmHg, and/or 80mmHg <= diastolic < 85mmHg; 4. 24kg/m2 < BMI < 27.9kg/m2; 5. Subject is required to voluntarily participate in the test of this program and sign the informed consent if the smart blood pressure watch meets the usage instructions; 6. People who do not take antihypertensive drugs; 7. Wrist circumference 130-200mm.

Exclusion criteria

Exclusion criteria: 1. Persons who do not have the ability to understand and control normal behaviors and cannot sign the informed consent; 2. Patients with upper limb or wrist infection or dark tattoo on the wrist; 3. Secondary hypertension; 4. Congenital heart disease, moderate and severe valvular disease, constrictive pericarditis, restrictive cardiomyopathy, coronary heart disease, patients after PCI; 5. Have been diagnosed with serious or uncontrollable arrhythmias (such as atrial fibrillation, atrial flutter, frequent premature beats, severe conduction block, etc.); 6. Patients with heart failure, that is, LVEF < 40% on echocardiography, NYHA grade II-IV; 7. Allergic; 8. Acute blood infection and systemic infection; 9. Patients with leukemia or malignant tumor and life expectancy less than 1 year; 10. Pregnant or lactating women; 11. There are mental diseases and intellectual disabilities that cannot cooperate with this researcher; 12. Patients with sleep apnea; 13. The investigator considers that any other reasons that may affect the efficacy and/or safety evaluation of the study are not suitable for the clinical trial (including but not limited to the investigator's judgment that the subject has poor compliance and cannot follow up regularly).

Design outcomes

Primary

MeasureTime frame
Blood Pressure;

Countries

China

Contacts

Public ContactYundai Chen

Chinese PLA General Hospital, Beijing, China

cyundai@vip.163.com+86 13311119778

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026